Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$881M |
| 2 |
DoorDash
DASH
|
+$403M |
| 3 |
Amgen
AMGN
|
+$403M |
| 4 |
Amazon
AMZN
|
+$282M |
| 5 |
Applied Materials
AMAT
|
+$231M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$592M |
| 2 |
Workday
WDAY
|
+$580M |
| 3 |
United Parcel Service
UPS
|
+$468M |
| 4 |
Apple
AAPL
|
+$438M |
| 5 |
Atlassian
TEAM
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.97% |
| 2 | Healthcare | 19.05% |
| 3 | Consumer Discretionary | 10.13% |
| 4 | Financials | 9.7% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Olema Pharmaceuticals
OLMA
$977M
| $13.8M | 0.01% |
1,221,662
+521,562
| +74% | +$6.73M |
|
627
Digital Realty Trust
DLR
$69.6B
| $13.8M | 0.01% |
95,626
+2,190
| +2% | +$310K |
|
628
Vanguard Total International Bond ETF
BNDX
$82B
| $13.8M | 0.01% |
279,666
-1,539
| -0.5% | -$75.2K |
|
629
Colgate-Palmolive
CL
$74.8B
| $13.7M | 0.01% |
151,939
-60,077
| -28% | -$5.09M |
|
|
KAMN
630
DELISTED
Kaman Corp
KAMN
| $13.6M | 0.01% |
297,210
+286,118
| +2,579% | +$11.7M |
|
631
Kornit Digital
KRNT
$677M
| $13.6M | 0.01% |
750,944
-8,925
| -1% | -$156K |
|
632
LoveSac
LOVE
$242M
| $13.6M | 0.01% |
601,870
-6,689
| -1% | -$156K |
|
|
SLN
633
Silence Therapeutics
SLN
$546M
| $13.6M | 0.01% |
+625,864
| New | +$13.6M |
|
634
Asure Software
ASUR
$242M
| $13.5M | 0.01% |
1,737,398
+1,043,385
| +150% | +$9.36M |
|
635
CryoPort
CYRX
$753M
| $13.5M | 0.01% |
761,772
-8,326
| -1% | -$132K |
|
636
Corbus Pharmaceuticals
CRBP
$165M
| $13.4M | 0.01% |
+339,074
| New | +$8.36M |
|
637
Emcor
EME
$29.9B
| $13.2M | 0.01% |
37,611
+15,066
| +67% | +$4.04M |
|
|
TERN
638
DELISTED
Terns Pharmaceuticals
TERN
| $13.1M | 0.01% |
2,003,263
+578,500
| +41% | +$3.78M |
|
639
Compass Therapeutics
CMPX
$349M
| $12.8M | 0.01% |
6,492,900
-54,331
| -0.8% | -$93.9K |
|
|
B
640
Barrick Mining
B
$60.9B
| $12.8M | 0.01% |
768,906
-10,000
| -1% | -$156K |
|
641
Savara
SVRA
$1.08B
| $12.8M | 0.01% |
2,563,620
+746,407
| +41% | +$3.61M |
|
642
Ecolab
ECL
$79.8B
| $12.6M | 0.01% |
54,756
-15,221
| -22% | -$3.23M |
|
643
Charles River Laboratories
CRL
$11.3B
| $12.6M | 0.01% |
46,571
-32,964
| -41% | -$7.87M |
|
644
Enliven Therapeutics
ELVN
$3.78B
| $12.6M | 0.01% |
713,911
+305,397
| +75% | +$4.69M |
|
645
AerCap
AER
$23.4B
| $12.4M | 0.01% |
142,539
+33,852
| +31% | +$2.66M |
|
646
US Bancorp
USB
$97.9B
| $12.4M | 0.01% |
276,599
+16,686
| +6% | +$704K |
|
647
CorVel
CRVL
$3.18B
| $12.4M | 0.01% |
140,925
+128,088
| +998% | +$10.3M |
|
648
Toronto Dominion Bank
TD
$193B
| $12.3M | 0.01% |
203,781
-142,105
| -41% | -$8.58M |
|
|
AXNX
649
DELISTED
Axonics, Inc. Common Stock
AXNX
| $12.3M | 0.01% |
178,322
+154,149
| +638% | +$10.4M |
|
650
Newmont
NEM
$96.2B
| $12.3M | 0.01% |
341,907
+54,761
| +19% | +$1.89M |
|
Similar funds
Janus Henderson Group's Q1 2024 Portfolio in Review
As of Q1 2024, Janus Henderson Group held 2,613 positions worth $183B, up 9.3% from $168B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Janus Henderson Group's Q1 2024 filing shows 67 new, 1,353 increased, 903 reduced and 85 closed positions. Its largest new stake was CG Oncology: 1,521,432 shares worth $66.8M. The largest sale was Abbott, an estimated $592M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q1 2024 buy was CG Oncology: 1,521,432 shares worth $66.8M.
- Janus Henderson Group added most to Oracle in Q1 2024, an estimated $881M increase.
- Janus Henderson Group's biggest Q1 2024 reduction was Abbott, cutting an estimated $592M.
- Janus Henderson Group fully exited Immunogen Inc in Q1 2024, selling an estimated $327M.
- Janus Henderson Group's ten largest holdings make up 28% of its $183B portfolio in Q1 2024.
- Janus Henderson Group opened 67 new positions and closed 85 in Q1 2024.
- Janus Henderson Group's portfolio value rose 9.3% quarter-over-quarter to $183B.
Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.